Study of Erythromycin in GER-Associated Apnea of the Newborn
NCT ID: NCT01825473
Last Updated: 2013-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2012-09-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laryngomalacia Study
NCT01782560
The Effect of Bethanechol on Tracheobronchomalacia
NCT05299008
The Nature of Reflux-respiratory Symptoms Association in Difficult to Treat Wheezing\Coughing Babies
NCT00512382
Premedication for Non-Emergency Endotracheal Intubation In the NICU
NCT01749501
Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)
NCT02453152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Erythromycin
50 mg/kg/day divided every 6 hours oral for 7 days
Erythromycin
Multi-channel intra-luminal impedance (MII) pH monitoring
Placebo
Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
Multi-channel intra-luminal impedance (MII) pH monitoring
Placebo (D5W)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythromycin
Multi-channel intra-luminal impedance (MII) pH monitoring
Placebo (D5W)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented symptoms of reflux
Exclusion Criteria
14 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Virginia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Faranek Davalian, MD
Neonatology Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fara Davalian, MD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia Children's Hospital
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16220
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.